Depressive Symptoms, Antidepressant Medication Use, and Insulin Resistance

The PPP-Botnia Study

ANTTI-JUSSI PYKKÖNEN, MA1,2 KATRI RAIKKONEN, PHD1 TIINAMAIJA TUOMI, MD, PHD1,2 JOHAN G. ERIKSSON, MD, PHD2,4,5,6,7 LEIF GROOP, MD, PHD4,6,7 BO ISOMAA, MD, PHD2,9

OBJECTIVE—Although insulin resistance (IR) may underlie associations between depressive symptoms and diabetes, previous findings have been contradictory. We examined whether depressive symptoms associate with IR and insulin secretion, and, additionally, whether antidepressant medication use may modulate such associations.

RESEARCH DESIGN AND METHODS—A total of 4,419 individuals underwent an oral glucose tolerance test (OGTT). Participants with previously or newly diagnosed diabetes are excluded from this sample. The homeostasis model assessment of IR (HOMA-IR) and corrected insulin response (CIR) were calculated. Depressive symptoms and antidepressant medication use were self-reported.

RESULTS—After controlling for confounding factors, depressive symptoms were associated with higher fasting and 30-min insulin during the OGTT and higher HOMA-IR but not CIR. Antidepressant medication use failed to modify these associations.

CONCLUSIONS—Depressive symptoms are associated with IR but not with changes in insulin response when corrected for IR in individuals without previously or newly diagnosed diabetes.

Depressive symptoms are associated with type 2 diabetes (1) and the metabolic syndrome (2,3), and insulin resistance (IR) is thought to be the underlying factor. However, previous findings have been conflicting because depressive symptoms have been reported to be associated with both higher IR (4) and lower IR (5), whereas some studies have reported null associations (6,7). We examined associations of depressive symptoms with IR and insulin secretion in individuals without diabetes. We also tested if antidepressant medications modulated these associations, as one study suggests that antidepressant medication, such as the use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, may improve insulin sensitivity (8). Yet, one study reported that antidepressant medications and insulin sensitivity are not related (9), whereas some studies have reported that antidepressant medications may decrease insulin sensitivity and increase the risk of type 2 diabetes (10,11).

IR and secretion

During an oral glucose tolerance test (OGTT) (75 g of glucose after a 12-h overnight fast), venous samples for plasma glucose (dehydrogenase method; Hemocue, Angelholm, Sweden) and insulin (fluoroimmunoassay, Delphia; PerkinElmer Finland, Turku, Finland) were drawn at 0, 30, and 120 min (means ± SD) 5.3 ± 0.6, 8.3 ± 1.5, and 5.2 ± 1.6 nmol/L and 6.6 ± 5.6, 59.7 ± 37.9, and 33.1 ± 35.6 μU/mL, respectively. The homeostasis model assessment of IR (HOMA-IR) (12) and corrected insulin response (CIR) (13) were calculated.

Depressive symptoms and use of antidepressant medications

Depressive symptoms were self-rated using the Short-Form 36/RAND-36 (14). We used the Mental Health Index (MHI), the Vitality Scale (VS), and their sum (20.0 ± 6.7, 9.8 ± 3.7, and 10.2 ± 3.7, respectively) to capture depressive symptoms. The rationale for calculating the sum was based on a Finnish validation study concluding that the VS items also characterize aspects of depression in a Finnish population (15). In the current study, the MHI and VS were significantly correlated (r = 0.70, P < 0.001).
We considered self-reported current use of SSRI-serotonin-norepinephrine reuptake inhibitor medication (n = 98), tricyclic medication (n = 36), tricyclic and SSRI-serotonin-norepinephrine reuptake inhibitor medication (n = 10), and antidepressant medications not specified (n = 3) as an indicator of the use of antidepressant medications (n = 147, 110 women and 37 men).

Statistical analyses
Logistic regression analyses, odds ratios (ORs), and 95% CIs were computed to examine associations with HOMA-IR and CIR as dichotomized (top/bottom quartiles vs. the other three). Multiple linear regression analyses examined associations with glucose and insulin during the OGTT.

Associations were adjusted first for sex and age and then additionally for regular exercise (yes: >30 min intense physical activity three or more times per week resulting in breathlessness/sweating vs. no: less or no activity), alcohol consumption (grams per week), current smoking status (yes vs. no or former smoker), BMI (kg/m²), occupational status (manual workers, junior clericals, senior clericals, students, and retirees), and family history of diabetes in at least one first-degree relative. Modulation by antidepressant medication use was examined by entering the interaction term “depressive symptoms × antidepressant medication use” into the regression equation followed by the main effects. Because we found no significant sex-interaction terms (all P values >0.26; data not shown), we report the results in both sexes combined.

RESULTS—The sample age averaged 48.5 ± 15.4 years, 52.6% were women, and the average BMI was 26.3 ± 4.3 kg/m². A total of 54.7% of subjects reported regular exercise; 14.7% reported smoking; 46.4 and 28.1% reported a weekly alcohol consumption of 12–60 g and >60 g, respectively; and 28.6 reported having a family history of diabetes. In addition, 17.4% of subjects were of senior clerical, 30.2% were of junior clerical, and 26.1% were of manual worker occupational status, whereas 21.8% were retired and 4.6% were students.

Depressive symptoms were associated with increased odds for antidepressant medication use (total score: OR 2.64 [95% CI 2.22–3.13]; MHI: 2.42 [2.05–2.85]; and VS: 2.52 [2.10–3.02]) per each SD unit increase in symptoms.

Antidepressant medication use was significantly associated with a higher odds for belonging to the top quartile of HOMA-IR but not with CIR (Table 1) or with insulin and glucose values during an OGTT (Supplementary Table A1) in models adjusted for confounding and mediating factors.

Although depressive symptoms were significantly associated with higher odds for belonging to the top quartile of HOMA-IR (Table 1), with higher fasting and 30-min insulin (Supplementary Table A1), they were not associated with CIR (Table 1) in models adjusted for confounding and mediating factors.

Analyses addressing interactions between antidepressant medication use and depressive symptoms showed that depressive symptoms were associated with higher 120-min glucose in participants using antidepressants (total score: 5.6% increase [95% CI 0.8–10.5], P = 0.02, and VS: 5.9% [0.08–11.0], P = 0.02, per SD unit increase in symptoms). In contrast, the associations were not significant in those who were not using antidepressants (P values >0.24) (P values <0.05 for antidepressant medication use × depressive symptoms – interactions). There were no additional significant interactions.

CONCLUSIONS—The current study examined the associations between depressive symptoms and IR and insulin secretion in a large, population-based sample of adult men and women without previously or newly diagnosed diabetes. Depressive symptoms were associated with higher odds for being insulin resistant but not with changes in insulin response when corrected for IR. These associations were not modulated by antidepressant medication use. Taken together, our findings suggest that depressive symptoms are associated with IR, even in individuals without diabetes, and that the use of antidepressant medications may neither augment nor explain these effects. Although our study was cross-sectional, constituting

### Table 1—Associations between depressive symptoms, the use of antidepressant medications, and HOMA-IR and CIR as indices of IR and secretion

|                        | HOMA-IR* | P     | CIR†  | P     |
|------------------------|----------|-------|-------|-------|
| Depression             |          |       |       |       |
| Antidepressant medication (no vs. yes)‡ |          |       |       |       |
| Sex- and age-adjusted model | 1.82 (1.29–2.58) | 0.001 | 1.21 (0.83–1.76) | 0.320 |
| Full model¶ | 1.66 (1.11–2.48) | 0.016 | 1.36 (0.92–2.01) | 0.121 |
| Depressive symptoms    |          |       |       |       |
| Total score (SD units) |          |       |       |       |
| Sex- and age-adjusted model | 1.17 (1.09–1.25) | 0.001 | 0.99 (0.92–1.06) | 0.681 |
| Full model¶ | 1.12 (1.03–1.21) | 0.007 | 0.98 (0.91–1.06) | 0.679 |
| MHI (SD units)         |          |       |       |       |
| Sex- and age-adjusted model | 1.11 (1.04–1.19) | 0.003 | 0.99 (0.93–1.07) | 0.848 |
| Full model¶ | 1.09 (1.01–1.18) | 0.038 | 0.99 (0.92–1.07) | 0.810 |
| Diagnosed diabetes excluded¶ | 1.20 (1.12–1.29) | 0.001 | 0.98 (0.91–1.05) | 0.496 |
| Full model¶ | 1.13 (1.04–1.22) | 0.004 | 0.98 (0.91–1.06) | 0.580 |

Data are OR (95% CI). *HOMA-IR was dichotomized contrasting the highest quartile (referent) with the other three quartiles, n = 1,105 vs. 3,314. †CIR was dichotomized contrasting the lowest quartile (referent) with the other three quartiles, n = 1,104 vs. 3,315. ‡Number of individuals using antidepressant medications is 147. ¶Full model refers to adjustments for age, sex, regular exercise (yes: >30 min intense physical activity three or more times per week resulting in breathlessness/sweating vs. no: less or no activity), alcohol consumption (grams per week), current smoking status (yes vs. no or former smoker), BMI (kg/m²), occupational status (manual workers, junior clericals, senior clericals, students, and retirees), and family history of diabetes in at least one first-degree relative.
An obvious and major study limitation, the fact that the associations characterized participants without diagnosed diabetes suggests that depressive symptoms should be regarded as a clinically important risk factor for both metabolic syndrome and type 2 diabetes. Thus, the detection and prevention of depressive symptoms are of importance in everyday clinical practice.

Additional study limitations include a lack of opportunity to address potential mechanisms underlying the reported associations, generalizability from our findings to non-whites, a lack of information regarding psychiatric disorders and/or the duration of antidepressant medication use, and the low prevalence of antidepressant medication use, which may have attenuated our ability to detect stronger associations, thereby limiting generalizability from the findings to less healthy populations.

In conclusion, depressive symptoms are associated with IR but not with changes in insulin response when corrected for IR in individuals without diabetes. Thus, the detection of individuals with higher depressive symptoms may benefit programs of early prevention of type 2 diabetes and related disorders.

Acknowledgments—The PPP-Botnia Study has been financially supported by grants from the European Science Foundation (EuroSTRESS), the Finnish Academy, the Sigrid Juselius Foundation, the Folkhälsan Research Foundation, the Nordic Center of Excellence in Disease Genetics, the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Finnish Diabetes Research Foundation, the Foundation for Life and Health in Finland, the Finnish Medical Society, the Finnish Ministry of Education, the Parvo Nurmi Foundation, the Perklen Foundation, the Olleprist Foundation, and the Närpes Health Care Foundation. The study also has been supported by the Municipal Health Care Center and Hospital in Jakobstad and Health Care Centers in Vasa, Närpes, and Korsholm.

J.G.E. has been a consultant and served on advisory boards for MSD, BMS, AstraZeneca, Roche, Eli Lilly, and Novo Nordisk. L.G. has been a consultant and served on advisory boards for sanofi-aventis, GlaxoSmithKline, Novartis, Merck, Tethys Bioscience, and XOMA and received lecture fees from Lilly and Novartis. No other potential conflicts of interest relevant to this article were reported.

A-J.P. researched data, contributed to discussion, and wrote the manuscript. K.R., T.T., J.G.E., L.G., and B.I. researched data, contributed to discussion, and reviewed and edited the manuscript.

The skillful assistance of the Botnia Study Group is gratefully acknowledged.

References

1. Rustad JK, Musse1 DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology 2011 [Epub ahead of print]
2. Pykkönen AJ, Raikkönen K, Tuomi T, Eriksson JG, Groop L, Isomaa B. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann Med 2011 [Epub ahead of print]
3. Raikkönen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care 2007; 30:872–877
4. Timonen M, Rajala U, Jokelainen J, Keinanen-Kiukaanniemi S, Meyer-Rochow VB, Rasani P. Depressive symptoms and insulin resistance in young adults: results from the Northern Finland 1966 birth cohort. Mol Psychiatry 2006;11:929–933
5. Lawlor DA, Smith GD, Ebrahim S; British Women’s Heart and Health Study. Association of insulin resistance with depression: cross sectional findings from the British Women’s Heart and Health Study. BMJ 2003;327:1383–1384
6. Lawlor DA, Ben-Shlomo Y, Ebrahim S, et al. Insulin resistance and depressive symptoms in middle aged men: findings from the Caerphilly prospective cohort study. BMJ 2005;330:705–706
7. Roos C, Lidfeldt J, Agardh CD, et al. Insulin resistance and self-rated symptoms of depression in Swedish women with risk factors for diabetes: the Women’s Health in the Lund Area Study. Metabolism 2007;56:825–829
8. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006;67:1856–1861
9. Chen YC, Lin WW, Chen YJ, Mao WC, Hung YJ. Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm 2010;2010:573594
10. Andersohn F, Schade R, Sussa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:591–598
11. Kivimaki M, Hamer M, Batty GD, et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33:2611–2616
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419
13. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190–198
14. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-item Health Survey 1.0. Health Econ 1993;2:217–227
15. Aalto A, Aro AR, Teperi J. RAND-36 as a Measure of Health-Related Quality of Life. Reliability, Construct Validity and Reference Values in the Finnish General Population. Helsinki, STAKES, 1999